MIGS devices market seen reaching $2.79 billion by 2030

The minimally invasive glaucoma surgery devices market is projected to grow from $0.89 billion in 2025 to $1.14 billion in 2026, then reach $2.79 billion by 2030, according to The Business Research Company. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region as demand rises for safer, faster-recovery glaucoma procedures.

Why it matters: - MIGS devices are gaining traction because they offer a less invasive way to lower intraocular pressure and manage glaucoma progression. - The market’s growth reflects rising glaucoma cases, an aging population and demand for procedures with fewer complications and faster recovery. - The category also benefits from more cataract surgeries and a shift toward outpatient eye care.

What happened: - The minimally invasive glaucoma surgery devices market is projected to rise from $0.89 billion in 2025 to $1.14 billion in 2026. - The forecast implies a 28.1% compound annual growth rate in 2026. - The market is expected to reach $2.79 billion by 2030, at a 24.9% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - MIGS devices use less invasive surgical approaches than conventional glaucoma procedures. - The devices are designed to reduce intraocular pressure while lowering complication risk and shortening recovery times. - The report points to broader adoption of MIGS for early and moderate-stage glaucoma. - MIGS is increasingly used alongside cataract surgery. - Outpatient and ambulatory glaucoma procedures are becoming more common. - Demand is rising for treatments with stronger safety profiles and faster recovery. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The Business Research Company offers a free sample report and the full market report.

Between the lines: - The growth outlook suggests MIGS is moving from a niche option to a more standard part of glaucoma treatment planning. - The strongest demand appears tied to procedures that preserve vision while reducing the burden of traditional surgery. - The National Eye Institute said approximately 2.2 million Americans will be blind or partially blind by 2030, underscoring the clinical need behind the market expansion.

What's next: - The market is likely to keep expanding as eye care clinics gain broader access and more patients seek outpatient surgical options. - Adoption should continue to increase in settings where MIGS can be paired with cataract surgery or used earlier in disease progression. - Asia-Pacific’s growth trajectory suggests more competition and investment opportunities outside North America.

The bottom line: - MIGS devices are becoming a fast-growing glaucoma treatment category, with double-digit growth expected through 2030 and demand supported by aging populations, rising eye disease prevalence and a shift toward safer surgery.